These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 37296644)

  • 21. Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis.
    Alqallaf A; Cates DW; Render KP; Patel KA
    Ann Pharmacother; 2024 Feb; 58(2):165-173. PubMed ID: 37269231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular insights and therapeutic targets in amyotrophic lateral sclerosis.
    Tripathi VB; Al-Chalabi A
    CNS Neurol Disord Drug Targets; 2008 Feb; 7(1):11-9. PubMed ID: 18289027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression.
    Bruneteau G; Simonet T; Bauché S; Mandjee N; Malfatti E; Girard E; Tanguy ML; Behin A; Khiami F; Sariali E; Hell-Remy C; Salachas F; Pradat PF; Fournier E; Lacomblez L; Koenig J; Romero NB; Fontaine B; Meininger V; Schaeffer L; Hantaï D
    Brain; 2013 Aug; 136(Pt 8):2359-68. PubMed ID: 23824486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series.
    Ketabforoush AHME; Chegini R; Barati S; Tahmasebi F; Moghisseh B; Joghataei MT; Faghihi F; Azedi F
    Biomed Pharmacother; 2023 Apr; 160():114378. PubMed ID: 36774721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospects for gene replacement therapies in amyotrophic lateral sclerosis.
    Giovannelli I; Higginbottom A; Kirby J; Azzouz M; Shaw PJ
    Nat Rev Neurol; 2023 Jan; 19(1):39-52. PubMed ID: 36481799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyotrophic lateral sclerosis: clinical management and research update.
    Andrews J
    Curr Neurol Neurosci Rep; 2009 Jan; 9(1):59-68. PubMed ID: 19080755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?
    Bassani D; Pavan M; Federico S; Spalluto G; Sturlese M; Moro S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tofersen for SOD1 ALS.
    Everett WH; Bucelli RC
    Neurodegener Dis Manag; 2024; 14(5):149-160. PubMed ID: 39330700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis.
    Jayasinghe M; Jena R; Singhal M; Jain S; Karnakoti S; Silva MS; Kayani AMA
    Cureus; 2022 Jun; 14(6):e25960. PubMed ID: 35855239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Riluzole and Edavarone: The Hope Against Amyotrophic Lateral Sclerosis.
    Rokade AV; Yelne P; Giri A
    Cureus; 2022 Oct; 14(10):e30035. PubMed ID: 36381733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Interprofessional Approach to Amyotrophic Lateral Sclerosis Care.
    Jaffa JL; Dufault M; Lavin M
    J Neurosci Nurs; 2017 Oct; 49(5):318-323. PubMed ID: 28817498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.
    Wobst HJ; Mack KL; Brown DG; Brandon NJ; Shorter J
    Med Res Rev; 2020 Jul; 40(4):1352-1384. PubMed ID: 32043626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
    Barp A; Gerardi F; Lizio A; Sansone VA; Lunetta C
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):145-164. PubMed ID: 32456491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.
    Goyal NA; Mozaffar T
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1541-51. PubMed ID: 24965719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stem cell therapy in amyotrophic lateral sclerosis.
    Meamar R; Nasr-Esfahani MH; Mousavi SA; Basiri K
    J Clin Neurosci; 2013 Dec; 20(12):1659-63. PubMed ID: 24148693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities.
    Soares P; Silva C; Chavarria D; Silva FSG; Oliveira PJ; Borges F
    Ageing Res Rev; 2023 Jan; 83():101790. PubMed ID: 36402404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropathological profile of long-duration amyotrophic lateral sclerosis in military Veterans.
    Spencer KR; Foster ZW; Rauf NA; Guilderson L; Collins D; Averill JG; Walker SE; Robey I; Cherry JD; Alvarez VE; Huber BR; McKee AC; Kowall NW; Brady CB; Stein TD
    Brain Pathol; 2020 Nov; 30(6):1028-1040. PubMed ID: 32633852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y; Shibuya K; Vucic S; Kiernan MC
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.